Physician profile
John J Wald
NPI 1275627366
$433,996.88
in general payments reported to CMS, 2019-2025
28 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $69K · 2021: $110K · 2022: $80K · 2023: $35K · 2024: $28K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Travel and Lodging: $6,680 · Food and Beverage: $3,445 · Consulting Fee: $3,285 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,402.90 |
| Travel and Lodging | $6,680.20 |
| Food and Beverage | $3,444.57 |
| Consulting Fee | $3,285.00 |
| Education | $267.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132,502.79 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $113,817.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $104,652.11 | 2019-2022 | |
| Amgen INC. | $44,228.42 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $16,027.89 | 2021 | |
| Genzyme Corporation | $14,504.77 | 2019-2023 | |
| Pfizer INC. | $4,890.74 | 2025 | |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Biogen, INC. | $605.18 | 2019-2025 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $444.11 | 2019-2022 | |
| Ucb, INC. | $239.50 | 2019-2023 | Nayzilam |
| Janssen Pharmaceuticals, INC | $228.07 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $226.57 | 2019-2021 | |
| Abbott Laboratories | $152.68 | 2021 | |
| Kyowa Kirin, INC. | $145.87 | 2023-2024 | Nourianz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $135.67 | 2019 | |
| Supernus Pharmaceuticals, INC. | $52.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.95 | 2022 | |
| Emd Serono, INC. | $30.69 | 2019-2021 | |
| Avion Pharmaceuticals | $27.25 | 2021 | |
| Celgene Corporation | $27.18 | 2021 | |
| Neurocrine Biosciences, INC. | $26.09 | 2021 | |
| Neurelis, INC. | $25.28 | 2021 | |
| Eisai INC. | $16.59 | 2019 | |
| Currax Pharmaceuticals LLC | $14.61 | 2021 | |
| Acorda Therapeutics, INC | $14.13 | 2019 | |
| Acadia Pharmaceuticals INC | $12.34 | 2019 | |
| Csl Behring | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.